Mortality Prognosis of Tuberculosis Patients with Comorbid Type 2 Diabetes Mellitus
Analysis
DOI:
https://doi.org/10.55175/cdk.v52i2.1248Keywords:
DM type 2, mortality, tuberculosisAbstract
Introduction: Indonesia ranks 3rd in tuberculosis (TB) cases in the world, and data from the Ministry of Health in 2020 showed that 10%-15% of TB sufferers had diabetes mellitus (DM). TB is one of the important causes of death, and DM affects the immune system which can increase the severity and mortality of the disease. This evidence-based case report was conducted to examine the mortality risk of tuberculosis patients with DM comorbidity. Methods: An article search was conducted to answer research questions based on 3 databases: PubMed, Cochrane, and ScienceDirect with the keywords “((Tuberculosis) AND (DM type 2) AND (Mortality))”. The search was based on inclusion and exclusion criteria and a critical review was conducted according to the guidelines for prognostic studies. Result: Tuberculosis patients with type 2 DM comorbidities have a 1.51 times higher risk of mortality compared to tuberculosis patients without type 2 DM comorbidities. Conclusion: Study by Huangfu, et al, (2019) can be the best choice to answer the clinical question that the risk of death of tuberculosis patients with comorbid DM increases by 1.51 times compared to patients without DM.
Downloads
References
Pedoman nasional pelayanan kedokteran tatalaksana tuberkulosis. Kementerian Kesehatan Republik Indonesia. Jakarta; 2020.
Amin Z, Bahar A. Tuberkulosis paru. In: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M, Setiati S, editors Buku ajar ilmu penyakit Dalam (jilid 1). 6th Ed. Jakarta: Balai Penerbit FKUI; 2014. p. 863-72.
Purnamasari D. Diagnosis dan klasifikasi diabetes melitus. In: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku ajar imu penyakit dalam (jilid 2). 6th Ed. Jakarta: Balai Penerbit FKUI; 2014. p. 2322.
Hasil utama RISKESDAS 2018. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan. Jakarta; 2018.
Restrepo BI. Diabetes and tuberculosis. Microbiol. Spectr. 2016;4(6):10.1128/microbiolspec.TNMI7-0023-2016. DOI: 10.1128/microbiolspec.TNMI7-0023-2016.
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442-9. DOI: 10.2174/1573399815666191024085838
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ. 2015;350:g7647. DOI: 10.1136/bmj.g7647
Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-nalysis. Int J Tuberc Lung Dis. 2019;23(7):783-96. DOI: 10.5588/ijtld.18.0433.
Magee MJ, Foote M, Maggio DM, Howards PP, Narayan KM, Blumberg HM, et al. Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012. Ann Epidemiol. 2014;24(5):369-75. DOI: 10.1016/j.annepidem.2014.01.012.
Nguyen CH, Pascopella L, Barry PM. Association between diabetes mellitus and mortality among patients with tuberculosis in California, 2010-2014. Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1269-76. DOI: 10.5588/ijtld.18.0011.
ROBINS-E Development Group (Higgins J, Morgan R, Rooney A, Taylor K, Thayer K, et al. Risk of bias in non-randomized studies - of exposure (ROBINS-E). Launch version, 20 June 2023. Available from: https://www.riskofbias.info/welcome/robins-e-tool.
Chiang CY, Bai KJ, Lin HH, Chien ST, Lee JJ, Enarson DA, et al. The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis. PLos One 2015;10: e0121698. DOI: 10.1371/journal.pone.0121698
Babalik A, Ulus I H, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob Agents Chemother. 2013; 57: 5740–2. DOI: 10.1128/AAC.01345-13
Kumar AKH, Chandrasekaran V, Kannan T, Murali AL, Lavanya J, Sudha V, et al. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. Eur J Clin Pharmacol. 2017; 73:65–70. DOI: 10.1007/s00228-016-2132-z.
Alsultan A, Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis: An update. Drugs 2014;74:2061. DOI: 10.1007/s40265-014-0222-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kemal Akbar Suryoadji, Ahmad Fauzi, Alifaturrasyid Syafaatullah Ridwan, Abdul Hafiidh Surya Putra, Wismandari Wisnu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
